Teva receives approval for Glipizide, Metformin

New York, Oct. 31 - Teva Pharmaceutical Industries Ltd. said it received approval from the Food and Drug Administration for its ANDA for pizide and Metformin Hydrochloride tablets, 2.5 mg/250 mg, 2.5 mg/500 mg and 5 mg/500 mg.

Shipment will begin immediately, the Jerusalem, Israel, generic pharmaceutical company said.

Glipizide and Metformin Hydrochloride tablets are the AB-rated generic equivalent of Bristol-Myers Squibb's Metaglip Tablets, which are indicated as an adjunct to diet and exercise in type 2 diabetes, as initial therapy or as a second-line therapy when response to sulfonylurea or metformin is inadequate.

The brand product has U.S. annual sales of $37 million, Teva said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.